Steroidal MRAs for patients with T2D with or without CKD are recommended only as antihypertensive treatments for patients who are resistant to angiotensin-converting enzyme inhibitor (ACEi) / angiotensin II receptor blockers (ARBs) plus a diuretic [30, 31]. Here, ACE is linked to type 2 diabetes mellitus.